- Home
- FEBO vs XAIR Comparison
FEBO vs XAIR Comparison
Compare FEBO & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FEBO | XAIR |
|---|---|---|
| Founded | 1993 | 2011 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8M | 10.1M |
| IPO Year | 2022 | 2015 |
Fundamental Metrics
Financial Performance| Metric | FEBO | XAIR |
|---|---|---|
| Price | $1.17 | $0.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 9.1K | ★ 163.9K |
| Earning Date | 04-24-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,705,000.00 |
| Revenue This Year | N/A | $122.00 |
| Revenue Next Year | N/A | $58.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 219.67 |
| 52 Week Low | $0.61 | $0.15 |
| 52 Week High | $1.48 | $3.78 |
Technical Indicators
Market Signals| Indicator | FEBO | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | 55.38 | 34.50 |
| Support Level | $1.04 | $0.76 |
| Resistance Level | $1.19 | $1.25 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 68.42 | 14.95 |
Price Performance
Historical ComparisonAbout FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances, principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.